Normal and tumor-derived organoids as a drug screening platform for tumor-specific drug vulnerabilities

STAR Protoc. 2022 Jan 10;3(1):101079. doi: 10.1016/j.xpro.2021.101079. eCollection 2022 Mar 18.

Abstract

Patient-derived tumor organoids can be predictive of patient's treatment responses, and normal tissue-derived organoids allow for drug toxicity testing. Combining both types of organoids therefore enables screening for tumor-specific drug vulnerabilities. Here, we provide a detailed protocol for organoid drug screening using, as proof-of-principle, patient-derived malignant rhabdoid tumor organoids. The protocol can be adapted for drug testing on any tumor and/or normal tissue-derived organoid culture. For complete details on the use and execution of this protocol, please refer to Calandrini et al. (2021).

Keywords: Cancer; Cell Biology; Health Sciences; High Throughput Screening; Organoids; Stem Cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Evaluation, Preclinical
  • Humans
  • Neoplasms* / drug therapy
  • Organoids* / pathology